Evidence map›Paper›PMID 30445121›Full record

ReviewAntiviral research2019

Vaccinating against monkeypox in the Democratic Republic of the Congo.

Brett W Petersen, Joelle Kabamba, Andrea M McCollum, Robert Shongo Lushima, Emile Okitolonda Wemakoy, Jean-Jacques Muyembe Tamfum, Beatrice Nguete, Christine M Hughes, Benjamin P Monroe, Mary G Reynolds

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Antiviral research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02977715 (An Open-Label Prospective Cohort Study of JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo), which is not on this map. Cited by 105 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 6 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02977715 phase3completednot on this map

An Open-Label Prospective Cohort Study of JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo

TypeinterventionalSponsorCenters for Disease Control and PreventionRan2017 to 2025Enrolled1,600ConditionsMonkeypox Virus InfectionArmsJYNNEOS (Liquid Formulation), JYNNEOS (Lyophilized Formulation)
3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 6 syntheses or guidelines pooled it, 225 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Brett W PetersenU.S. Centers for Disease Control and Prevention, Atlanta, USA. Electronic address: bpetersen@cdc.gov.
Joelle KabambaU.S. Centers for Disease Control and Prevention, Kinshasa, Democratic Republic of the Congo.
Andrea M McCollumU.S. Centers for Disease Control and Prevention, Atlanta, USA.
Robert Shongo LushimaHemorrhagic Fever and Monkeypox Program, Ministry of Health, Kinshasa, Democratic Republic of the Congo.
Emile Okitolonda WemakoyKinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo.
Jean-Jacques Muyembe TamfumNational Institute for Biomedical Research, Kinshasa, Democratic Republic of the Congo.
Beatrice NgueteKinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo.
Christine M HughesU.S. Centers for Disease Control and Prevention, Atlanta, USA.
Benjamin P MonroeU.S. Centers for Disease Control and Prevention, Atlanta, USA.
Mary G ReynoldsU.S. Centers for Disease Control and Prevention, Atlanta, USA.
Centers for Disease Control and Prevention · USMinistry of Public Health · CDNational Institute of Biomedical Research · CD

Funding

Intramural CDC HHS CC999999NCEZID CDC HHS U01 CK000539
6 · The paper itself

Abstract

Healthcare-associated transmission of monkeypox has been observed on multiple occasions in areas where the disease is endemic. Data collected by the US Centers for Disease Control and Prevention (CDC) from an ongoing CDC-supported program of enhanced surveillance in the Tshuapa Province of the Democratic Republic of the Congo, where the annual incidence of human monkeypox is estimated to be 3.5-5/10,000, suggests that there is approximately one healthcare worker infection for every 100 confirmed monkeypox cases. Herein, we describe a study that commenced in February 2017, the intent of which is to evaluate the effectiveness, immunogenicity, and safety of a third-generation smallpox vaccine, IMVAMUNE

Indexed as

Health PersonnelAnimalsClinical Trials as TopicDemocratic Republic of the CongoHealth ResourcesHumansImmunogenicity, VaccineMonkeypox virusMpox, MonkeypoxOccupational DiseasesRisk FactorsRural PopulationSmallpox VaccineVaccinationVaccines, Attenuatedsmallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordicSmallpox VaccineVaccines, AttenuatedClinical trialDemocratic Republic of the CongoIMVAMUNEMonkeypoxSmallpox vaccine

Identifiers

PMID30445121
PMCPMC6438175
OpenAlexW2901488134

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.